Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 133-142

  Jiang, Tao ^a,c   Zhou, Changdong ^b   Gu, Junlian ^d   Liu, Yanan ^d   Zhao, Lijing ^d   Li, Wei ^a   Wang, Guanjun ^a   Li, Yang ^d   Cai, Lu ^a,e  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b People's Hospital of Jilin Province   (China)

^c Jilin Province People's Hospital   (China)

^d Basic Medical College   (China)

^e University of Louisville School of Medicine   (United States)

Author keywords

Apoptosis; Cisplatin (DDP); P53; Prostate cancer; Si RNA mdm2; Xenograft mice model

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; PLASMID VECTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MDM2 GENE; MOUSE; NONHUMAN; P53 GENE; PRIORITY JOURNAL; PROSTATE CANCER; SALMONELLA;

APOPTOSIS; CISPLATIN (DDP); P53; PROSTATE CANCER; SI RNA-MDM2; XENOGRAFT MICE MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COMBINED MODALITY THERAPY; GENES, P53; GENETIC THERAPY; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, SMALL INTERFERING; SALMONELLA TYPHIMURIUM;

MUS; SALMONELLA;

EID: 84880037112     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.028     Document Type: Article

References (46)

1. Desireddi N.V., Roehl K.A., Loeb S., Yu X., Griffin C.R., Kundu S.K., Han M., Catalona W.J. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007, 70:950-955.
2. Svatek R.S., Lee J.J., Roehrborn C.G., Lippman S.M., Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008, 112:1058-1065.
3. Patel A.R., Sandler H.M., Pienta K.J. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clin. Genitourin. Cancer 2005, 4:212-214.
4. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., de Wit R., Tannock I.F., Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 2007, 13:6396-6403.
5. Calabro F., Sternberg C.N. Current indications for chemotherapy in prostate cancer patients. Eur. Urol. 2007, 51:17-26.
6. Nakabayashi M., Sartor O., Jacobus S., Regan M.M., McKearn D., Ross R.W., Kantoff P.W., Taplin M.E., Oh W.K. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008, 101:308-312.
7. Ross R.W., Beer T.M., Jacobus S., Bubley G.J., Taplin M.E., Ryan C.W., Huang J., Oh W.K. Prostate cancer clinical trials consortium. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008, 112:521-526.
8. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 1998, 34:1535-1542.
9. Rossi A., Maione P., Gridelli C. Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Expert Opin. Drug Saf. 2005, 4:1051-1067.
10. Perrotta C., Bizzozero L., Falcone S., Rovere-Querini P., Prinetti A., Schuchman E.H., Sonnino S., Manfredi A.A., Clementi E. Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res. 2007, 67:7559-7564.
11. Cross D., Burmester J.K. Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 2006, 4:218-227.
12. Vousden K.H., Lane D.P. P53 in health and disease. Nat. Rev. Mol. Cell. Biol. 2007, 8:275-283.
13. Tao W., Levine A.J. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 1999, 96:3077-3080.
14. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006, 13:921-926.
15. Mu Z., Hachem P., Agrawal S., Pollack A. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate 2004, 60:187-196.
16. Mu Z., Hachem P., Agrawal S., Pollack A. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:336-343.
17. Mu Z., Hachem P., Hensley H., Stoyanova R., Kwon H.W., Hanlon A.L., Agrawal S., Pollack A. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate 2008, 68:599-609.
18. Stoyanova R., Hachem P., Hensley H., Khor L.Y., Mu Z., Hammond M.E., Agrawal S., Pollack A. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:1151-1160.
19. Wade M., Wahl G.M. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?. Mol. Cancer Res. 2009, 7:1-11.
20. Ji K., Wang B., Shao Y.T., Zhang L., Liu Y.N., Shao C., Li X.J., Li X., Hu J.D., Zhao X.J., Xu D.Q., Li Y., Cai L. Synergistic Suppression of prostatic cancer cells by co-expression of both Mdm2-siRNA and wide-type P53 gene in vitro and in vivo. J. Pharmacol. Exp. Ther. 2011, 338:173-183.
21. Pawelek J.M., Low K.B., Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997, 57:4537-4544.
22. Low K.B., Ittensohn M., Le T., Platt J., Sodi S., Amoss M., Ash O., Carmichael E., Chakraborty A., Fischer J., Lin S.L., Luo X., Miller S.I., Zheng L., King I., Pawelek J.M., Bermudes D. Lipid a mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat. Biotechnol. 1999, 17:37-41.
23. Sorenson B.S., Banton K.L., Frykman N.L., Leonard A.S., Saltzman D.A. Attenuated Salmonella typhimurium with interleukin 2 gene prevents the establishment of pulmonary metastases in a model of osteosarcoma. J. Pediatr. Surg. 2008, 43:1153-1158.
24. Yuhua L., Kunyuan G., Hui C., Yongmei X., Chaoyang S., Xun T., Daming R. Oral cytokine gene therapy against murine tumor using attenuated Salmonella typhimurium. Int. J. Cancer. 2001, 94:438-443.
25. Jiang Z., Zhao P., Zhou Z., Liu J., Qin L., Wang H. Using attenuated Salmonella typhi as tumor targeting vector for MDR1siRNA delivery. Cancer Biol. Ther. 2007, 6:555-560.
26. Zhang L., Gao L., Zhao L., Guo B., Ji K., Tian Y., Wang J., Yu H., Hu J., Kalvakolanu D.V., Kopecko D.J., Zhao X., Xu D.Q. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella entericaserovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res. 2007, 67:5859-5864.
27. Jia H., Li Y., Zhao T., Li X., Hu J., Yin D., Guo B., Kopecko D.J., Zhao X., Zhang L., Xu D.Q. Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol. Immunother. 2012, 61:1977-1987.
28. Zhang L., Gao L., Li Y., Lin G., Shao Y., Ji K., Yu H., Hu J., Kalvakolanu D.V., Kopecko D.J., Zhao X., Xu D.Q. Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3 M tumor cell growth. Clin. Cancer Res. 2008, 14:559-568.
29. Hohmann E.L., Oletta C.A., Killeen K.P., Miller S.I. PhoP/phoQ-deleted Salmonella typhi(Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 1996, 173:1408-1414.
30. Gao Z.N., Wei Y.Q., Yang P.S., Xu X., Zhao H.Q., Huan X., Kang B. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. Oral Oncol. 2007, 43:477-483.
31. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
32. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 2003, 3:102-109.
33. Gottifredi V., Prives C. Molecular biology, getting p53 out of the nucleus. Science 2001, 292:1851-1852.
34. Yu Y., Sun P., Sun L.C., Liu G.Y., Chen G.H., Shang L.H., Wu B.H., Hu J., Li Y., Mao Y.L., Sui G.J., Sun X.W. Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin. Biochem. Biophys. Res. Commun. 2006, 339:71-78.
35. Isaacs W.B., Carter B.S., Ewing C.M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991, 51:4716-4720.
36. Hainaut P., Hollstein M. P53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77:81-137.
37. Moll U.M., Wolff S., Speidel D., Deppert W. Transcription-independent proapoptotic functions of p53. Curr. Opin. Cell. Biol. 2005, 17:631-636.
38. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
39. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 2001, 7:673-682.
40. Sax J.K., Fei P., Murphy M.E., Bernhard E., Korsmeyer S.J., El-Deiry W.S. BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. 2002, 4:842-849.
41. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U.M. P53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003, 11:577-590.
42. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
43. Moorsel C.J.A., Pinedo H.M., Veerman G., Vermorken J.B., Postmus P.E., Peters G.J. Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur. J. Cancer. 1999, 35:808-811.
44. Ma Y.P., Yang Y., Zhang S., Chen X., Zhang N., Wang W., Cao Z.X., Jiang Y., Zhao X., Wei Y.Q., Deng H.X. Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP. J. Exp. Clin. Cancer Res. 2010, 29:56.
45. Li J., Gong C., Feng X., Zhou X., Xu X., Xie L., Wang R., Zhang D., Wang H., Deng P., Zhou M., Ji N., Zhou Y., Wang Y., Wang Z., Liao G., Geng N., Chu L., Qian Z., Wang Z., Chen Q. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One 2012, 7:e33860.
46. Roh J.L., Ko J.H., Moon S.J., Ryu C.H., Choi J.Y., Koch W.M. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett. 2012, 325:35-41.